Drug intelligence / Profile preview

bacTRL-IL-12

Development stage: Discontinued
Lead developer: IQVIA
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

bacTRL-IL-12 is a novel, genetically engineered bacterial therapy designed to deliver interleukin-12 (IL-12) directly to tumor sites. The therapy uses a modified strain of Bifidobacterium longum that encodes the IL-12 transgene. Upon administration, these bacteria selectively colonize hypoxic regions within solid tumors and locally release IL-12, aiming to stimulate an anti-tumor immune response while minimizing systemic toxicity[1][3]. IL-12 is a cytokine known for its ability to activate both innate and adaptive immunity by promoting T helper 1 (Th1) responses, enhancing cytotoxic T lymphocyte and natural killer cell activity, and increasing interferon-gamma production[5][6]. The primary indication for bacTRL-IL-12 has been advanced solid tumors. Development was initially led by IQVIA Ltd., but the global highest R&D status is currently listed as discontinued[2].

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on bacTRL-IL-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacTRL-IL-12.

Explore the full profile